Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. LAL PATHLABS Plunges 3%; BSE HEALTHCARE Index Down 0.3%
Mon, 12 Aug 10:8

DR. LAL PATHLABS Plunges 3%; BSE HEALTHCARE Index Down 0.3%Image source: ipopba/www.istockphoto.com

DR. LAL PATHLABS share price has plunged 3% and is presently trading at Rs 3,109.7.

Meanwhile, the BSE HEALTHCARE index is at 40,938.4 (down 0.3%).

Among the top losers in the BSE HEALTHCARE index today are Cadila Healthcare (down 3.0%) and ALEMBIC PHARMA (down 2.4%).

SUVEN PHARMACEUTICALS (up 3.0%) and CAPLIN POINT (up 2.5%) are among the top gainers today.

Over the last one year, DR. LAL PATHLABS has moved up from Rs 2,368.1 to Rs 3,109.7, registering a gain of Rs 741.6 (up 31.3%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,343.8 to 40,938.4, registering a gain of 44.4% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 114.1%), GSK Pharma (up 105.9%) and GRANULES INDIA (up 105.5%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 79,265.6 (down 0.6%).

The top losers among the BSE Sensex today are MUNDRA PORT & SEZ (down 2.6%) and NTPC (down 2.1%). The most traded stocks in the BSE Sensex are Tata Steel and MUNDRA PORT & SEZ.

In the meantime, NSE Nifty is at 24,242.4 (down 0.5%). Adani Enterprises and MUNDRA PORT & SEZ are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,846.5 to 79,265.6, registering a gain of 13,419.1 points (up 20.4%).

DR. LAL PATHLABS Financial Update...

DR. LAL PATHLABS net profit grew 28.9% YoY to Rs 1,078 million for the quarter ended June 2024, compared to a profit of Rs 836 million a year ago. Net sales rose 11.3% to Rs 6,019 million during the period as against Rs 5,410 million in April-June 2023.

For the year ended March 2024, DR. LAL PATHLABS reported 50.3% increase in net profit to Rs 3,623 million compared to net profit of Rs 2,411 million during FY23. Revenue of the company grew 10.4% to Rs 22,266 million during FY24.

The current Price to earnings ratio of DR. LAL PATHLABS, based on rolling 12 month earnings, stands at 67.2.


Equitymaster requests your view! Post a comment on "DR. LAL PATHLABS Plunges 3%; BSE HEALTHCARE Index Down 0.3%". Click here!